{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:48:16Z","timestamp":1773974896217,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00277-019-03741-8","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T09:17:35Z","timestamp":1561627055000},"page":"2339-2346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-1686","authenticated-orcid":false,"given":"Massimiliano","family":"Bonifacio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Montemezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"De Matteis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Bertorelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Scaffidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Candiotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Zam\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Chilosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pizzolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"issue":"10","key":"3741_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M (2004) Life expectancy and prognostic factors for survival in patients with polycytemia vera and essential thrombocytemia. Am J Med 117(10):755\u2013761. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2004.06.032","journal-title":"Am J Med"},{"issue":"25","key":"3741_CR2","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Sch\u00f6negger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"issue":"25","key":"3741_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"issue":"20","key":"3741_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. \n                    https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"10","key":"3741_CR5","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NCC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'Antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M, on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544\u20131551. \n                    https:\/\/doi.org\/10.1182\/blood-2013-11-539098","journal-title":"Blood"},{"issue":"23","key":"3741_CR6","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ESG, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, M\u00fcllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179\u20133184. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.34.5298","journal-title":"J Clin Oncol"},{"issue":"1","key":"3741_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2015.192","volume":"30","author":"H Stein","year":"2016","unstructured":"Stein H, Bob R, D\u00fcrkpo H, Erck C, K\u00e4mpfe D, Kvasnicka HM et al (2016) A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies. Leukemia 30(1):131\u2013135. \n                    https:\/\/doi.org\/10.1038\/leu.2015.192","journal-title":"Leukemia"},{"issue":"9","key":"3741_CR8","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/leu.2014.100","volume":"28","author":"AM Vannucchi","year":"2014","unstructured":"Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M et al (2014) Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia 28(9):1811\u20131818. \n                    https:\/\/doi.org\/10.1038\/leu.2014.100","journal-title":"Leukemia"},{"issue":"4","key":"3741_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pathol.2016.03.002","volume":"48","author":"J Andrici","year":"2016","unstructured":"Andrici J, Farzin M, Clarkson A, Sioson L, Sheen A, Watson N, Toon CW, Koleth M, Stevenson W, Gill AJ (2016) Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms. Pathology 48(4):319\u2013324. \n                    https:\/\/doi.org\/10.1016\/j.pathol.2016.03.002","journal-title":"Pathology"},{"issue":"4","key":"3741_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/ajcp\/aqw135","volume":"146","author":"L Nomani","year":"2016","unstructured":"Nomani L, Bodo J, Zhao X, Durkin L, Loghavi S, Hsi ED (2016) CAL2 immunohistochemical staining accurately identifies CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol 146(4):431\u2013438. \n                    https:\/\/doi.org\/10.1093\/ajcp\/aqw135","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"3741_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437\u2013438. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404914","journal-title":"Leukemia"},{"issue":"3","key":"3741_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2450\/2009.0070-08","volume":"7","author":"D Veneri","year":"2009","unstructured":"Veneri D, Capuzzo E, De Matteis G, Franchini M, Baritono E, Benati M et al (2009) Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Blood Transfus 7(3):204\u2013209. \n                    https:\/\/doi.org\/10.2450\/2009.0070-08","journal-title":"Blood Transfus"},{"issue":"10","key":"3741_CR13","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/leu.2009.108","volume":"23","author":"G Kanellis","year":"2009","unstructured":"Kanellis G, Roncador G, Arribas A, Mollejo M, Montes-Moreno S, Maestre L, Campos-Martin Y, R\u00edos Gonzalez JL, Martinez-Torrecuadrada JL, Sanchez-Verde L, Pajares R, Cigudosa JC, Martin MC, Piris MA (2009) Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia 23(10):1847\u20131857. \n                    https:\/\/doi.org\/10.1038\/leu.2009.108","journal-title":"Leukemia"},{"issue":"6","key":"3741_CR14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/his.12871","volume":"68","author":"HM Kvasnicka","year":"2016","unstructured":"Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, Kremer M, Schmitt-Graeff A, Schwarz S, Thiele J, Werner M, Stein H (2016) Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis \u2013 a consensus-based study. Histopathology 68(6):905\u2013915. \n                    https:\/\/doi.org\/10.1111\/his.12871","journal-title":"Histopathology"},{"key":"3741_CR15","unstructured":"R Core Team (2015) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL \n                    http:\/\/www.R-project.org\/\n                    \n                  . Accessed 25 June 2019"},{"issue":"1","key":"3741_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A (2015) Myeloproliferative neoplasms. A contemporary review. JAMA Oncol 1(1):97\u2013105. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.89","journal-title":"JAMA Oncol"},{"issue":"1","key":"3741_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.leukres.2014.11.019","volume":"39","author":"AV Jones","year":"2015","unstructured":"Jones AV, Ward D, Lyon M, Leung W, Callaway A, Chase A, Dent CL, White HE, Drexler HG, Nangalia J, Mattocks C, Cross NCP (2015) Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res 39(1):82\u201387. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2014.11.019","journal-title":"Leuk Res"},{"issue":"8","key":"3741_CR18","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 vs type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121\u2013E124. \n                    https:\/\/doi.org\/10.1002\/ajh.23743","journal-title":"Am J Hematol"},{"issue":"1","key":"3741_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/leu.2014.270","volume":"29","author":"X Cabagnols","year":"2015","unstructured":"Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O (2015) Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocythemia: relevance for disease evolution. Leukemia 29(1):249\u2013252. \n                    https:\/\/doi.org\/10.1038\/leu.2014.270","journal-title":"Leukemia"},{"issue":"5","key":"3741_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/bjh.13638","volume":"173","author":"L Riera","year":"2016","unstructured":"Riera L, Osella-Abate S, Benevolo G, Beggiato E, Ferrero S, Pich A, Francia di Celle P (2016) Novel CALR somatic mutations in essential thrombocythemia. Br J Haematol 173(5):797\u2013801. \n                    https:\/\/doi.org\/10.1111\/bjh.13638","journal-title":"Br J Haematol"},{"issue":"22","key":"3741_CR21","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1182\/blood.V128.22.5499.5499","volume":"128","author":"P Butylin","year":"2016","unstructured":"Butylin P, Matyuhina N, Lisina E, Siordia N, Senderova O, Lomaia E, Zaritskey A (2016) Calreticulin mutations variants of ET and PMF patients studied in Almazov Medical Center Russian Federation. Blood 128(22):5499 (ASH annual meeting abstracts)","journal-title":"Blood"},{"issue":"2","key":"3741_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C et al (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30(2):431\u2013438. \n                    https:\/\/doi.org\/10.1038\/leu.2015.277","journal-title":"Leukemia"},{"issue":"23","key":"3741_CR23","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1182\/blood.V126.23.2822.2822","volume":"126","author":"Y Xu","year":"2015","unstructured":"Xu Y, Kwok B, Yung A, Flamholz R, Wu Z, Dabbas B, Reddy P (2015) Clinicopathologic analysis of CALR mutation subtypes in myeloproliferative neoplasms. Blood 126(23):2822 (ASH annual meeting abstracts)","journal-title":"Blood"},{"issue":"5","key":"3741_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.24338","volume":"91","author":"YC Elala","year":"2016","unstructured":"Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, Abou Hussein AK, Hanson CA, Ketterling RP, Pardanani A, Tefferi A (2016) Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol 91(5):503\u2013506. \n                    https:\/\/doi.org\/10.1002\/ajh.24338","journal-title":"Am J Hematol"},{"issue":"5","key":"3741_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069. \n                    https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"issue":"9","key":"3741_CR26","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M (2010) A prospective study on 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease tranformation and vascular complications. Leukemia 24(9):1574\u20131579. \n                    https:\/\/doi.org\/10.1038\/leu.2010.148","journal-title":"Leukemia"},{"issue":"2","key":"3741_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc1401255","volume":"371","author":"B Cassinat","year":"2014","unstructured":"Cassinat B, Verger E, Kiladjian JJ (2014) Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 371(2):188\u2013189. \n                    https:\/\/doi.org\/10.1056\/NEJMc1401255","journal-title":"N Engl J Med"},{"issue":"5","key":"3741_CR28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/bjh.12904","volume":"166","author":"K Haslam","year":"2014","unstructured":"Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E (2014) Assessment of CALR mutations in myelofibrosis patients post allogeneic stem cell transplantation. Br J Haematol 166(5):800\u2013802. \n                    https:\/\/doi.org\/10.1111\/bjh.12904","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03741-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03741-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03741-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T23:17:39Z","timestamp":1593127059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03741-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3741"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03741-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"23 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Bonifacio declares research funding from Novartis and received speaker bureau and advisory board honorarium from Amgen, Bristol-Myers Squibb, Incyte, Novartis and Pfizer, outside the present study. All the other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}